Pfizer's arthritis contender tofacitinib faces possible US approval delay
02:20 EDT 1 Aug 2012 | SCRIP
A US FDA approval decision may be delayed for Pfizer's novel, oral JAK-inhibitor tofacitinib - which could give the blockbusters Enbrel (etanercept), Humira (adalimumab) and other TNF-inhibitors a run for their money in the rheumatoid arthritis (RA..
Original Article: Pfizer's arthritis contender tofacitinib faces possible US approval delay
More From BioPortfolio on "Pfizer's arthritis contender tofacitinib faces possible US approval delay"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
